Skip Navigation LinksHome > July 2011 - Volume 26 - Issue 4 > Pregabalin augmentation in treatment-resistant obsessive–com...
International Clinical Psychopharmacology:
doi: 10.1097/YIC.0b013e3283466657
Short Communication

Pregabalin augmentation in treatment-resistant obsessive–compulsive disorder

Oulis, Panagiotis; Mourikis, Iraklis; Konstantakopoulos, George

Collapse Box


The therapeutic limitations of mainstay psychopharmacological treatments of obsessive–compulsive disorder (OCD) warrant the clinical testing of further add-on agents to improve patients' clinical symptoms. One such agent might be pregabalin, which has been found efficacious in other anxiety disorders. We report on the findings of a small, 8-week open-label trial of adjunctive pregabalin with a 4-week follow-up in 10 OCD patients resistant or only partial responders to a combination of serotonin reuptake inhibitors with atypical antipsychotics. Adjunctive pregabalin at 225–675 mg/d was well tolerated and led to patients' substantial improvement in their OCD symptoms, as reflected in their scores on the Yale–Brown Obsessive Compulsive Scale. Despite the several limitations of the study, its results suggest that adjunctive pregabalin might be a safe and efficacious new augmentation agent in the treatment of drug-resistant OCD. We hypothesize that pregabalin's mechanism of action in OCD might consist in its inhibition of glutamatergic neurotransmission.

© 2011 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.